Par Pharmaceutical Investor Sues To Halt $1.9B TPG Deal
A Par Pharmaceutical Cos. Inc. shareholder launched a class action in Delaware court on Tuesday challenging private equity firm TPG Capital's $1.9 billion bid to take the generic-drug maker private, calling...To view the full article, register now.
Already a subscriber? Click here to view full article